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ABSTRACT
The continuing threat of infectious disease and
future pandemics, coupled to the continuous
increase of drug-resistant pathogens, makes the
discovery of new and better vaccines imperative.
For effective vaccine development, antigen discov-
ery and validation is a prerequisite. The compilation
of information concerning pathogens, virulence
factors and antigenic epitopes has resulted in
many useful databases. However, most such
immunological databases focus almost exclusively
on antigens where epitopes are known and
ignore those for which epitope information was
unavailable. We have compiled more than 500
antigens into the AntigenDB database, making use
of the literature and other immunological resources.
These antigens come from 44 important pathogenic
species. In AntigenDB, a database entry contains
information regarding the sequence, structure,
origin, etc. of an antigen with additional information
such as B and T-cell epitopes, MHC binding,
function, gene-expression and post translational
modifications, where available. AntigenDB also
provides links to major internal and external
databases. We shall update AntigenDB on a rolling
basis, regularly adding antigens from other
organisms and extra data analysis tools.
AntigenDB is available freely at http://www.imtech
.res.in/raghava/antigendb and its mirror site
http://www.bic.uams.edu/raghava/antigendb.
INTRODUCTION
The term vaccine can be applied to all agents, either of
a molecular or supramolecular nature, used to stimulate
speciﬁc, protective immunity against pathogenic microbes
and the disease they cause. It is clear that vaccines form
the most powerful and cost-eﬀective prophylactic therapy
for infectious disease. Vaccines work to militate against
the eﬀects of subsequent infection as well as blocking
the ability of a pathogen to kill its host. The availability
of entire genomes corresponding to many important
pathogens has instigated a new research initiative able to
discover a wide array of antigens, which can act as poten-
tial vaccine candidates. Bioinformatics, in the form of
comprehensive immunological databases and analysis
tools, has hastened both the identiﬁcation and the valida-
tion of candidate vaccines.
Previously, the principal means of antigen discovery
was empirical. A live, virulent pathogen, for example, is
now considered a poor candidate vaccine since despite
its potent immunogenicity it is more liable to induce
disease than to prevent or treat it. Thus, vaccines have,
until recently, been primarily attenuated or chemically
inactivated whole pathogen vaccines such as Sabin’s
polio vaccine or BCG. More recently, safety concerns
have fostered alternate strategies for vaccine development.
The most successful has focused on the antigen,
acellular or subunit vaccine, which includes recombinant
vaccines against hepatitis B, human papillomavirus and
Haemophilus inﬂuenzae B. Subunit vaccines are typically
composed of immunogenic protein or carbohydrate, such
as cell wall components, or a bio-conjugated combination
of both. Many antigens are highly immunogenic, while
others stimulate measurable yet often weak responses,
requiring boosting to perpetuate long-term protection
and the addition of adjuvants (1–3).
Antigen-based subunit vaccines long ago became
a prime focus on vaccine discovery. Approaches to the
identiﬁcation of antigens include the identiﬁcation
of immunodominant epitopes, assaying for enhanced
correlates of protection such as antibody levels and
cytokine production and testing for enhanced survival in
disease challenge models. Long, cumbersome and incon-
clusive procedures for antigen validation currently in use,
compounded by the failure to identify protective B cell or
T cell mediated epitopes, are often unsuccessful, failing to
detect eﬃciently an antigen as an eﬃcacious vaccine can-
didate. Thus the identiﬁcation of antigens as putative
whole protein subunit vaccines is also now a key goal of
immunoinformatics and computational vaccinology.
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eliciting signiﬁcant responses from both humoral and
cellular immune systems, far exceeding the eﬃcacy of
peptide vaccines, while avoiding the potential toxicity
problems associated with whole microbe vaccines. A nec-
essary step towards systematizing antigen discovery is the
rigorous compilation and annotation of antigens.
Recently, massive factory-scale experimentation
coupled to literature mining has allowed numerous func-
tional immunology databases to emerge. Databases such
as The Immune Epitope Database and Analysis Resource
(IEDB), MHCBN, AntiJen and BCIPEP (4–7) are large,
robust data repositories and provide copious information.
Concerning antigens, however, these databases, although
replete with information concerning individual B cell
epitopes, T cell epitopes and Major Histocompatibility
Complex (MHC) binding peptides, remain otherwise
partial and incomplete. Their focus is on the epitope,
and not the antigen. There are many antigens, for which
speciﬁc epitope or MHC binding information is not
currently available, yet many such antigens are known
experimentally to induce either or both innate or
adaptive immune responses. Such antigens—or similar
pathogenic proteins—might prove useful in vaccine
design. These antigens require urgent and rigorous
cataloguing.
In order to address this pressing issue, the present work
describes the database AntigenDB. It is a specialized,
value-added database of antigens derived from pathogenic
organisms. This resource is intended to be a repository for
all experimentally determined antigens, irrespective of
whether such an antigen is associated within the extant
knowledge-base with known epitope data. The database
is freely accessible through a web browser at http://www
.imtech.res.in/raghava/antigendb/.
SYSTEM AND METHODS
Database construction and architecture
Experimentally validated antigens were collected
from the literature (PubMed: http://www.ncbi.nlm.nih
.gov/pubmed/; ScienceDirect: http://www.sciencedirect
.com/). Additional information about these antigens was
collected from various public databases including IEDB,
MHCBN, AntiJen and BCIPEP. We developed PERL
scripts to extract sequence, structural, functional and
gene expression information from SwissProt, GenBank,
PDB (Protein Data Bank) and GEO databases (8–11).
AntigenDB is built on a SUN systems T-1000 under
Solaris 10.0 environment. The front-end was developed
using HTML and the backend was developed using
PostgreSQL, a relational database management system.
All common gateway interface (CGI) and database
interfacing scripts were written in the PERL programming
language. The architecture of AntigenDB database is
shown in Figure 1a and b.
Organization of data
AntigenDB collects and compiles comprehensive infor-
mation concerning antigens. Most of the antigens in
AntigenDB come from the genus Mycobacterium,
Plasmodium and the Inﬂuenza A virus (Figure 2).
The up-to-date status of the database is available at url:
http://www.imtech.res.in/raghava/antigendb/info.html.
Data for each antigen can be categorized as primary data
(antigen sequence and structural information), B cell
epitope (epitope sequence and antibody information), T
cell epitope (T helper and T killer cell epitopes, MHC I/II
binding and TAP binding and cleavage sites information),
function (cellular location, function, functional sites and
similarity with host and pathogens), Gene expression
(nucleotide sequence, codon frequency and expression
proﬁles) and diﬀerent types of Post-translational modiﬁ-
cation (PTM) associated with antigens. Each antigen is
assigned a unique entry number and information is
divided into six tables; each table providing unique
information.
General information. The main or primary table contains
general information about antigens. This table has the
following main ﬁelds: (i) antigen name: the name of the
antigen with its synonyms; (ii) antigen type: whether it is
protein, carbohydrate or lipid; (iii) amino acid sequence of
protein antigen and (iv) source organism of origin, with a
link to the NCBI taxonomy database.
Structural information. Within the database, detailed
crystal structure information is available for 290 molecules
out of 504 antigens. This information is supplemented by
the OCA web browser (http://oca.weizmann.ac.il), with
surface accessibility provided by ASAView tools (12).
We also link to the Swiss-model repository database
(13), which provides hypothetical structures for unsolved
protein using protein-modeling techniques. We also
provide secondary structure information in the form of
percent content as calculated by DSSP (14).
B-cell epitope. A principal challenge for immunology is
to identify antigenic regions, responsible for simulating
B-cells, also called B-cell epitopes (15). We have collected
B-cell epitopes reported for antigens available in
AntigenDB (Figure S1). This table has the following
major ﬁelds: (i) the capability of antigen to induce B cell
or humoral immune responses; (ii) speciﬁc B-cell epitopes
within the antigen; (iii) the antibodies that recognize these
epitopes and (iv) PTMs associated with such epitopes.
Most of the data for this table has been obtained from
the primary literature or from a secondary source
(BCIPEP and IEDB). Many antigens have no known
B-cell epitopes; these antigens are not covered by B-cell
epitope databases.
T-cell epitope. Most extant vaccines are mediated
by antibodies. However, responses to diseases without
eﬀective vaccines are largely mediated by cellular—not
humoral—immunology. Thus, to develop subunit
vaccines one needs to identify T-cell epitopes within an
antigen. Figure S2 shows the distribution of T cell
epitopes in antigenDB; most antigens have less than 10
T-cell epitopes. The T-cell epitope table contains the fol-
lowing main ﬁelds: (i) immunogenicity induced due to T
D848 Nucleic AcidsResearch, 2010, Vol.38,Database issuehelper or Cytotoxic T cells; (ii) Helper or cytotoxic T cell
epitopes; (iii) PTMs associated with these epitopes; (iv)
MHC I/II binders with experimental IC50 values if avail-
able; (v) TAP binders mapping and (vi) mapping of
cleavage sites. Data for this table was obtained from the
literature, and from the MHCBN, IEDB and AntiJen
databases. Both B and T-cell epitopes are linked directly
to other epitope databases, such as the IEDB. There are
358 antigens for which there is no epitope information;
this means these antigens are not covered in existing
epitopes databases. There are about 95 antigens of genus
Mycobacterium, alone which are shown to induce immune
response, but for which no epitope has yet been identiﬁed.
This demonstrates the importance of AntigenDB, which
covers experimentally-validated, protective antigens not
covered in epitope-oriented databases.
Figure 1. (a) Overall architecture of AntigenDB. (b) Detailed information for each antigen entry.
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determines potential candidacy as a vaccine. If the
antigen is involved in house-keeping or is present at the
cell surface and easily available to surveillance by the host
immune system then the probability that an antigen will be
suitable vaccine candidate increases. Therefore, there is
an imperative need to have insight into the function and
subcellular localization of each antigen. The function table
provides the following information: (i) functional annota-
tion of antigens using SwissProt and GO databases;
(ii) Cellular localization (secreted, cytoplasmic and
membrane bound) as described in DBSubLoc and
PSORTdb (16,17) databases and (iii) functional sites and
domains obtained from InterPro (18). The development of
a better vaccine requires knowledge of the similarity
between candidate antigen and others derived from the
host or other pathogenic organisms. If an antigen is simi-
lar to one or more host proteins there exists the possibility
of autoimmune responses; less similarity with other
pathogens is also advantageous and would qualify the
antigen as a better vaccine candidate. Therefore, we
provide a BLAST (19) results for each antigen with patho-
genic and human proteins.
Gene expression. Suitable antigens are often highly
expressed and thus optimally available to host surveil-
lance. Expression of any protein is largely dependent on
the codon usage of that organism (20). Therefore,
AntigenDB provides information about: (i) Gene
sequence as obtained from GenBank; (ii) codon frequency
of genes; (iii) codon bias calculated using Graphical codon
usage analyzer (GCUA) (21) and (iv) expression proﬁles
of antigen obtained from databases such as GEO (11).
Post-translational modiﬁcation. PTMs aﬀect the expres-
sion and function of antigens. Therefore diﬀerent types
of PTMs are covered in the database. The major PTMs
covered include: (i) N/O/C/S-Glycosylation; (ii) Phos-
phorylation; (iii) Amidation site; (iv) N-Myristoylation;
(v) Tyrosine Sulfation and (vi) Methylation and other
PTMs. These are compiled from the literature as well as
specialized databases such as dbPTM, PhosphoELM, and
RESID (22–24).
IMPLEMENTATION
Currently, AntigenDB contains an extensive collection of
proteins, glycoproteins and lipoproteins (in excess of 500),
extracted from 44 important pathogenic species. This
covers following major genuses; Mycobacterium,
Inﬂuenza A virus, Helicobacter, Bacillus, Brucella,
Clostridium, Hepatitis, Plasmodium, Streptococcus,
Yersinia and Vibrio (Figure 2).
AntigenDB entries are cross-linked to a variety of key
databases, such as SwissProt, GenBank, IMGT (25),
SYFPEITHI (26), AntiJen, DBSubLoc, PSORT and the
PDB. In AntigenDB, diﬀerent types of useful web tools
have been provided. There are many tools integrated into
AntigenDB for the extraction and analysis of antigens.
These include searching the AntigenDB database, the
analysis of antigen data through mapping, and data
submission.
Data search and analysis
AntigenDB is complemented by an array of tools, which
facilitate further analysis of antigens (Figure 3).
AntigenDB is user-friendly and can be searched using
Figure 2. Antigen distribution in AntigenDB database.
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organisms name. Users of AntigenDB can quickly
extract useful information from the database in two
diﬀerent ways: (i) via Keyword search and (ii) via
Browsing.
Keyword search. The keyword search allows a user to
search for antigens using the ﬁve digits AntigenDB entry
number, antigen name, SwissProt accession number or by
entering a source microorganism to list all the available
antigens present in that pathogen. A query can be ﬁltered
further by selecting the antigen type among the protein,
carbohydrate and lipid antigens or by selecting the speciﬁc
organism from the drop down menu. A query returns a
tabular output whose format depends upon the ﬁelds
selected initially, with an option of exporting the search
result as a data ﬁle.
Browsing. Browing is a very useful tool in database, which
can be searched easily by selecting organism of interest
and output ﬁelds. It returns all the available antigens
present for that pathogen.
Antigenic BLAST
The Antigenic blast page provides users with an oppor-
tunity to search a query protein sequence against the
AntigenDB database for the purposes of sequence com-
parison. The standalone WWW-BLAST program is care-
fully integrated into AntigenDB for this purpose, and has
a customizable weight matrix and E score threshold.
Peptide mapping
The peptide-mapping tool allows users to ask whether
a query protein contains any already known antigenic
epitopes. The tool scans all the epitopes present in the
AntigenDB database against the query protein and
returns the starting and ending position of experimentally
deﬁned epitopes corresponding to the query protein
Figure 3. Flow of data searching and result reporting. From AntigenDB home page to data search using keyword ‘protective’ and display of results.
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where returned epitopes were derived.
Epitope search
The epitope search enables users to ask whether a query
epitope sequence is present in known antigens within the
database. This tool searches for exact or similar epitopes
in the database. It returns AntigenDB antigens in which
such epitopes are present.
Data submission
The online data submission tool allows users to submit a
newly identiﬁed antigen not present in the AntigenDB
database. Submitted antigens are included in AntigenDB
after validation.
DISCUSSION AND CONCLUSIONS
AntigenDB should prove of value to a variety of
researchers: immunoinformaticians developing new and
enhanced methods for the prediction of antigens (27,28);
vaccine development scientists searching for antigens in
newly deﬁned pathogens or novel candidate vaccine
antigens in well known pathogenic microorganisms and
microbiologists analyzing virulence mechanisms in patho-
genic microorganisms, amongst others.
AntigenDB is a repository for experimentally deter-
mined antigens. It is the ﬁrst of its kind; in contrast to
existing epitope-orientated database, AntigenDB
emphasizes experimentally-veriﬁed antigens, irrespective
of whether epitope information is known or unknown.
The database provides useful analysis tools able to
search and map an unknown protein for similarity to
known antigens or experimentally determined epitopes.
We have and continue to undertake exhaustive literature
searches in order to cover as many antigens as possible,
yet it remains possible that certain antigens are missing
from the database. Initially, we intended to cover all
pathogenic species, but realized quickly that this was an
impractical approach. Instead, we have selected species
with an impact on global health and antigens, which are
available in the literature and other sources. Several
species were also selected whose close relatives were
already present in the database. To enable faster
database accesss, we have created a mirror site
at http://www.bic.uams.edu/raghava/antigendb/. The
current database mainly contains protein antigens. This
is inﬂuenced by the easy availability of such antigens
within the current literature.
We anticipate that this thorough and comprehensive
database will be extended to eﬀective completeness, and
then maintained and its content expanded, with constantly
enhanced search and analysis features added on a rolling
basis. For example, where available we will add experi-
mental data derived from the literature and archived
microarray experiments relating to the expression of
antigens in the next release of AntigenDB. Certain impor-
tant viral pathogens—such as Hepatitis A, Hepatitis B,
Hepatitis E, Herpes simplex virus and Human
adenovirus—and other antigen types will be included in
future releases of the database.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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